Mometasone 25micrograms/dose / Olopatadine 600micrograms/dose nasal spray

The recent approval of the nasal spray combination of mometasone (MOM) and olopatadine (OLO) presents a significant analytical challenge, as only a single reported method exists for its determination, deviating from eco-friendly practices. This study addresses this critical gap by pioneering the application of machine learning techniques to develop robust UV spectrophotometric approach for the simultaneous quantification of MOM and OLO, along with two genotoxic impurities: 4-dimethylamino pyridine (DAP) and methyl para-toluene sulfonate (MTS). By simultaneously determining these highly concerning genotoxic impurities and active pharmaceutical ingredients, this method underscores its paramount significance in upholding rigorous pharmaceutical quality standards and safeguarding patient safety. Applying the multilevel-multifactor experimental design, the calibration set was meticulously chosen at five different concentrations, yielding 25 calibration mixtures with central levels of 4, 46.5, 2.5, and 3 µg/mL for MOM, OLA, MTS, and DAP, respectively. The key innovation lies in the strategic implementation of the Kennard-Stone Clustering Algorithm to create a robust validation set of thirteen mixtures, resolving the limitations of reported chemometric methods' random data splitting. This approach ensures unbiased evaluation across the full concentration space, improving the method's reliability and sustainability. The robustness of this approach was rigorously tested using five distinct chemometric models: principal component regression, classical least squares, partial least squares, genetic algorithm-partial least squares, and multivariate curve resolution-alternating least squares, demonstrating its broad applicability across diverse modeling techniques. All models successfully determined all components with excellent recovery, low bias-corrected prediction, and adequate limits of detection. The Greenness Index Spider Charts and the Green Solvents Selection Tool were used to choose environmentally conscious solvents. A comprehensive sustainability assessment employed six state-of-the-art tools, including the national environmental method index, complementary green analytical procedure index, analytical greenness metric, blue applicability grade index, carbon footprint analysis, and the red-green-blue 12 metrics. Favorable results across all metrics affirmed the method's eco-friendliness, real-world applicability, and cost-effectiveness, supporting sustainable development goals in pharmaceutical quality control processes.

Abstract licence: CC BY-NC-ND 4.0

PurposeCombination intranasal corticosteroid and antihistamine sprays are a first-line treatment option for allergic rhinitis (AR), of which Azelastine Hydrochloride and Fluticasone Propionate nasal spray (AZE/FLU; Dymista®), and Olopatadine Hydrochloride and Mometasone Furoate Monohydrate nasal spray (OLO/MOM; Ryaltris®) are currently registered in Australia. As it is not known how patients value treatment attributes of current combination nasal sprays, this observational, real-world clinical study aimed to understand patients' satisfaction with, and importance of, treatment attributes of OLO/MOM and AZE/FLU using an Anchored Best-Worst Scaling (ABWS) exercise.Participants and methodsFour hundred and twenty-six adults in Australia with moderate to severe AR using either OLO/MOM or AZE/FLU completed an online survey incorporating an ABWS with 11 domains: 7 sensory (immediate taste of medication, aftertaste of medication, smell of medication, irritation to your nose, urge to sneeze, dripping out your nose/down your throat, dryness of your nose/throat) and 4 treatment-related (convenience, fast acting, duration of effect, and AR symptom control). The ABWS involved rescaling individual BWS scores using anchored ratings (0-10) for most and least satisfied/important domains to create a total satisfaction index (TSI) (0-100) to be compared across groups. Statistical comparisons were completed using ANOVA (TSI) and MANOVA (individual domains).ResultsParticipants using OLO/MOM (M = 68.26, SE = 1.39) had significantly higher TSI than participants using AZE/FLU (M=62.78, SE = 0.70) (p p ConclusionCurrent findings showed that participants using OLO/MOM were more satisfied with their overall treatment compared to participants using AZE/FLU, particularly with sensory attributes, thus highlighting the suitability of OLO/MOM for people with AR who value sensory attributes. Prescribers of AR treatments are encouraged to discuss treatment attributes with patients to facilitate shared decision-making.

Abstract licence: CC BY-NC 3.0